<Research>BofAS Elevates SINO BIOPHARM's TP to HKD5.1; Rating Reiterated Buy
Close
2025/05/28 06:15 GMT
Recommend
23
Positive
46
Negative
21
 
SHORT SELL
 
STOCK INFO

BofA Securities has issued a research report raising its target price for SINO BIOPHARM (01177.HK)  +0.080 (+1.818%)    Short selling $151.67M; Ratio 21.529%   from HKD4.4 to HKD5.1, with a Buy rating reiterated, given more clinical proof of efficacy obtained by the company, its robust sales performance in March, and its announcement that QP001 (meloxicam injection) has recently received marketing approval from China's NMPA and the US FDA.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-03 16:25.)

Related NewsBOCOMI: Many CN Innovative Drugs to Announce Blockbuster Data at ASCO Meeting w/ Record High No. of Selected CN Innovative Drug

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>BofAS Elevates SINO BIOPHARM's TP to HKD5.1; Rating Reiterated Buy
BofA Securities has issued a research report raising its target price for SINO BIOPHARM (01177.HK) from HKD4.4 to HKD5.1, with a Buy rating reiterated, given more clinical proof of...
Reset
Send
The window will close in 5 seconds